Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The objective of the study is to investigate the clinical validity of tau-PET with \[18F\]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 85
Healthy Volunteers: f
View:
• Written Inform Consent to participating.
• 50 to 85 years of age
• a diagnosis of Mild Cognitive Impairment (MCI=at least one pathological neuropsychological test but no functional impairment based on the Amsterdam IADL score) or mild dementia (both cognitive and functional impairments)
• availability of MRI within 6 months before screening
• prescription of a diagnostic amyloid PET
• Willing and able to comply with the requirements of the study, as judged by the investigator.
Locations
Other Locations
Switzerland
Geneva University Hospital
RECRUITING
Geneva
Centre Medical Universitaire Vaudois
RECRUITING
Lausanne
Contact Information
Primary
Valentina Garibotto, MD
valentina.garibotto@hug.ch
+41223727252
Time Frame
Start Date: 2024-12-03
Estimated Completion Date: 2027-08-30
Participants
Target number of participants: 120
Treatments
Experimental: Amyloid-PET and then Tau-PET
The participant will have the Amyloid-PET (standard of care) and then Tau-PET (experimental)
Experimental: Tau-PET and then Amyloid-PET
The participant will have the Tau-PET (experimental) and then the Amyloid-PET (standard of care)
Related Therapeutic Areas
Sponsors
Collaborators: Centre Hospitalier Universitaire Vaudois
Leads: University Hospital, Geneva